Parkinson’s may be several diseases under one name
Parkinson’s disease has long been treated as a single disorder defined mainly by the symptoms people experience: movement problems, neurological decline, and the gradual loss of everyday function. A new study led by researchers at VIB and KU Leuven makes the case that this clinical label hides deeper biological diversity. Using machine learning, the team says Parkinson’s can be organized into two broad molecular groups and then split further into five smaller subgroups.
The finding matters because one of the field’s persistent frustrations is that treatments aimed at one pathway often do not work broadly across the entire Parkinson’s population. According to the researchers, that mismatch may reflect a basic problem of classification. If patients grouped together under the same diagnosis actually have different underlying molecular mechanisms, then a single therapeutic strategy was always unlikely to fit all of them.
Why the new classification could matter
The study, published in Nature Communications, starts from a reality neurologists have known for years: Parkinson’s can be linked to mutations in many different genes. Those differences have complicated drug development, because the disease can look similar at the clinical level while being driven by different biology underneath. The Leuven team argues that the molecular signatures are distinct enough to support a more targeted model of care.
Lead researchers say the new framework identifies two broad subgroups of parkinsonism that can be divided into five smaller categories. That does not replace the diagnosis clinicians use today, but it suggests the umbrella term may be too blunt for the next generation of therapies. In practical terms, the work points toward stratified treatment, where future drugs could be chosen according to the molecular dysfunction involved rather than the symptom cluster alone.
An unbiased approach to a messy disease
Rather than beginning with a theory about which mutations should belong together, the team used an “unbiased” analysis. Researchers observed fruit fly models carrying Parkinson’s-related mutations over time and then applied computational and machine-learning tools to detect patterns in behavior and disease progression. The point was to let the data cluster the mutations instead of forcing them into pre-existing categories.
That approach is notable because Parkinson’s research has often been pushed toward specific mechanisms one at a time. The new study instead tries to build a map of relationships across genetically different forms of the disease. If those clusters hold up in additional work, they could help explain why some promising treatments help a subset of patients but fail to produce uniform results in larger populations.
From symptom-based medicine to mechanism-based medicine
The broader implication is conceptual as much as clinical. Parkinson’s may still present to doctors as a recognizable syndrome, but at the molecular level it could be better understood as a collection of related conditions. That shift is increasingly common across medicine, where cancers, autoimmune diseases, and neurodegenerative disorders are being broken into biologically meaningful subtypes.
For Parkinson’s, the promise is precision. Better subclassification could improve trial design, reduce the chance of mixing biologically different patients in the same study, and make it easier to test drugs against the specific dysfunctions they are built to address. It could also help explain uneven patient experiences, including why disease progression and treatment response vary so widely from person to person.
What comes next
The study does not deliver a new therapy on its own, and it does not suggest that the current clinical definition of Parkinson’s is useless. What it does offer is a more granular biological framework that may help researchers rethink both diagnosis and drug development. Before that framework changes care, the field will need to test how well these groupings translate beyond model organisms and into patient populations.
Even so, the result is a meaningful step. Parkinson’s has been stubbornly difficult to treat with one-size-fits-all solutions. By showing that genetically different forms of the disease can be grouped into reproducible molecular classes, the study gives the field a sharper starting point. If the classification proves robust, the future of Parkinson’s treatment may look less like one disease, one drug, and more like a portfolio of therapies matched to distinct biological subtypes.
This article is based on reporting by Medical Xpress. Read the original article.
Originally published on medicalxpress.com
